Skip to main content
. Author manuscript; available in PMC: 2015 Jun 19.
Published in final edited form as: Pain. 2010 Aug 1;151(1):174–183. doi: 10.1016/j.pain.2010.07.003

Fig. 2. Effect of ETB-R agonist or ETA/B-R antagonists on ET-induced SNB.

Fig. 2

Two days after I/R injury, sham (A and B) and CPIP (C and D) mice received a 10 μl i.pl. injection of vehicle (white histogram), BQ-123 (light grey histogram, 5 or 10 nmol, ETA-R antagonist), BQ-788 (dark grey histogram, 30 or 60 nmol, ETB-R antagonist) or IRL-1620 (black histogram, 50 or 200 pmol, ETB-R agonist). Twenty minutes later, they received a 10 μl i.pl. injection of endothelin-1 (ET-1, A: 70 pmol for sham and C: 7 pmol for CPIP) or endothelin-2 (ET-2, B: 200 pmol for sham and D: 125 pmol for CPIP). The total sustained nociceptive behavior score (SNB score) was determined over a period of 30 minutes. N=7–8/group (* p<0.05, ** p<0.01, one-way ANOVA followed by a Dunnett’s t-test). BQ-123 and IRL-1620 reduced, and BQ-788 enhanced, ET-1/2-induced SNBs in CPIP mice, while BQ-123 also reduced ET1/2-induced SNBs in shams.